UniQure NV (QURE) Common Stock EUR0.05
2.20%- This stock can be held in a
Stocks and Shares ISA
$0.12
(0.93%)$0.12
(0.93%)Company Information
About this company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Key people
Key facts
- EPIC-
- LocationNetherlands
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINNL0010696654
- Market cap$712.75m
- Employees480
- Shares in issue53.15m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.